文献速递贫血与红细胞疾病

供者特征与受者脾活性降低镰状细胞病红细胞输注存活

Red blood cell transfusion survival in sickle cell disease is reduced by donor characteristics and recipient spleen activity.
PubMed 文献 · Blood Adv · 2026-01-01

该观察性临床试验用生物素标记法测量镰状细胞病(SCD)患者输注的红细胞存活期,发现输注后24小时中位恢复率为97.3%,28天为80%,90天为21%,中位50%恢复时间为60天;受者脾体积和供者G6PD缺乏或α-地中海贫血特质与红细胞存活降低相关。

要点

  • SCD慢性输血患者中,供者红细胞90天中位存活仅21%。
  • 受者脾体积增大和供者G6PD缺乏/α-地中海贫血特质降低红细胞存活。
  • 受者红细胞同种免疫与存活降低呈非显著关联。

核心结论

  • 供者和受者特征可降低输注红细胞存活,可能影响输血效果和SCD管理。

研究设计与样本

  • 观察性临床试验,纳入儿童和成人SCD慢性输血患者,用生物素标记法测量供者红细胞寿命。

主要发现

  • 输注后24小时中位恢复率97.3%(范围79.4%-112.7%),28天80%(范围35%-105%),90天21%(范围2%-48%)。
  • 中位50%恢复时间为60天(范围23-85天)。
  • 多变量混合效应分析中,受者脾体积和供者G6PD缺乏或α-地中海贫血特质与生物素标记红细胞存活降低相关。
  • 多变量分析中,受者红细胞同种免疫与红细胞存活降低呈非显著关联。

临床怎么用

  • 输血时应考虑供者G6PD缺乏或α-地中海贫血特质及受者脾体积对红细胞存活的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Red blood cell (RBC) transfusion therapy in sickle cell disease (SCD) is used to treat and prevent disease complications by providing nonsickle erythrocytes that survive for weeks in circulation. The suppression of sickle hemoglobin between transfusion episodes is dependent on donor RBC survival. We present an observational clinical trial of transfusion survival in pediatric and adult patients with SCD receiving chronic transfusion therapy using biotin-labeling to measure donor RBC life span. For each transfusion episode, aliquots from 2 to 3 RBC units were separated from each unit, biotin-labeled at 2, 6, or 18 μg/mL, and transfused to the patient after the main RBC unit. Biotin-labeled RBCs (B-RBC) were analyzed by flow cytometry at 15 minutes, 24 hours, and weekly through 16 weeks after transfusion. Recipient splenic volume was assessed by ultrasound. Glucose-6-phosphate dehydrogenase (G6PD) enzyme activity and hemoglobinopathy status were determined for each RBC unit. Twenty recipients received a total of 22 B-RBC transfusion episodes (49 units). Median posttransfusion recovery was 97.3% (range, 79.4%-112.7%) at 24 hours, 80% (range, 35%-105%) at 28 days, and 21% (range, 2%-48%) at 90 days. Median time to 50% recovery was 60 days (23-85 days). In multivariate mixed-effects analysis, recipient spleen volume and donor G6PD deficiency or α-thalassemia trait were associated with decreased B-RBC survival. Recipient RBC alloimmunization showed a nonsignificant association with decreased RBC survival in multivariate analysis. Donor and recipient characteristics that reduce RBC survival have the potential to affect transfusion effectiveness and SCD management and require future studies in larger cohorts. This trial was registered at www.clinicaltrials.gov as #NCT04426591.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yee MEM, Zerra PE, Francis RO, et al. Red blood cell transfusion survival in sickle cell disease is reduced by donor characteristics and recipient spleen activity. Blood Adv. 2026. PMID: 42018645. doi:10.1182/bloodadvances.2025019005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。